Akums Drugs and Pharmaceuticals has unveiled a groundbreaking fixed-dose combination (FDC) medication designed to tackle resistant hypertension effectively.

The newly introduced Amlodipine, Telmisartan & Metoprolol (ER) film-coated tablets amalgamate three established drugs into a single pill, offering a convenient solution for blood pressure control.

"This FDC underscores our steadfast commitment to enhancing patient outcomes in the fight against hypertension," stated Sandeep Jain, Managing Director of Akums Drugs and Pharmaceuticals.

The medication, approved by the Drug Controller General of India (DCGI), brings together a calcium channel blocker, an angiotensin II receptor antagonist, and a beta-blocker, addressing various facets of blood pressure regulation. By combining these agents into a single pill, Akums aims to streamline treatment and enhance patient adherence.

"We are confident that this innovative formulation will revolutionize hypertension management," remarked Sanjeev Jain, Managing Director of Akums Drugs and Pharmaceuticals.

With hypertension being a significant global health concern, Akums' new FDC offers a promising avenue for optimizing patient care and improving treatment outcomes. The company's commitment to innovation and patient-centric solutions underscores its dedication to advancing healthcare standards.